CMS Biosimilars Guidance

CMS Biosimilars Guidance

Earlier this week the Centers for Medicare & Medicaid Services (CMS) issued four guidance documents detailing how Medicare Parts B and D as well as the Medicaid Drug Rebate Program will treat biosimilar therapies.

 Download CMS guidance documents.

About NASP | Contact Us | Privacy Policy

©2016-2019 National Association of Specialty Pharmacy
300 New Jersey Avenue NW, Suite 900
Washington, D.C. 20001